Panel: When Innovation Outruns Infrastructure
Day 3 Next-Gen Bio Stage
08/10/2026 10:30 - 11:15am
Contributors
Carmen Sanges : EU Initiatives Scientific Project Lead - University Hospital Würzburg / T2EVOLVE Association
Tanya Sharma : Co-founder - Assurea
Lindsay Davies : CEO - QVance
Volker Huppert : Member - Act for Hope Foundation
Scientific progress in advanced therapies is accelerating, but the operational systems required to support that progress — manufacturing capacity, regulatory coordination, capital allocation, and market readiness — are evolving more gradually. As complexity increases, scalability has become a defining variable in commercial success.
Manufacturing readiness now influences investment decisions. Regulatory alignment shapes time to market. Capital discipline increasingly reflects operational feasibility.
This session examines whether the broader ecosystem is adapting quickly enough to sustain the next generation of therapies — and what structural shifts are required to align innovation with real-world execution.
Key discussion points include:
- Manufacturing as a strategic differentiator rather than a back-end function.
- Investment models adapting to capital-intensive development pathways.
- System readiness as a competitive advantage.
- Cross-stakeholder coordination to reduce execution risk.